Mavorixafor + Placebo

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Jun 6, 2024 → Nov 1, 2027

NCT ID

NCT06056297

About Mavorixafor + Placebo

Mavorixafor + Placebo is a phase 3 stage product being developed by X4 Pharmaceuticals for Neutropenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06056297. Target conditions include Neutropenia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06056297	Phase 3	Recruiting	Jun 6, 2024	Nov 1, 2027	Neutropenia
NCT03995108	Phase 3	Active	Oct 24, 2019	Dec 1, 2025	WHIM Syndrome

Competing Products

20 competing products in Neutropenia

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	85
pegfilgrastim	Kyowa Kirin	Phase 2	52
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	77
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	52
Imipenem + Imipenem	Merck	Approved	85
Posaconazole IV solution + Posaconazole powder for oral suspension	Merck	Phase 1	33
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	85
Ceftolozane-tazobactam IV	Merck	Approved	85
Daptomycin + Daptomycin	Merck	Phase 3	77
pegfilgrastim	Amgen	Phase 3	76
Neulasta (pegfilgrastim)	Amgen	Approved	84
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	84
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	32
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	32
linezolid + vancomycin	Pfizer	Phase 3	76
Anidulafungin	Pfizer	Phase 1/2	40
Nivestim®	Pfizer	Pre-clinical	22
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	22
Voriconazole	Pfizer	Phase 1/2	40
Filgrastim Hospira (US) + U.S.-approved Neupogen®	Pfizer	Phase 1	32

Other Products from X4 Pharmaceuticals

Mavorixafor + PlaceboPhase 3

X4P-001Phase 2

MavorixaforPhase 1/2

X4P-001 + NivolumabPhase 1/2

X4P-001 + axitinibPhase 1/2